ACAD

16.37

1.17% 0.19

Dopo l'orario di chiusura: 16.40 0.03 +0.18%

Acadia Pharmaceuticals Inc (ACAD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ACAD Giù? Forum Previsione

Precedente Chiudi:

$16.18

Aprire:

$16.15

Volume 24 ore:

1.36M

Relative Volume:

1.04

Capitalizzazione di mercato:

$2.72B

Reddito:

$890.53M

Utile/perdita netta:

$30.57M

Rapporto P/E:

-17.79

EPS:

-0.92

Flusso di cassa netto:

$80.53M

1 W Prestazione:

-2.39%

1M Prestazione:

+12.74%

6M Prestazione:

+3.48%

1 anno Prestazione:

-25.56%

Intervallo 1D:

$16.01

$16.69

Intervallo di 1 settimana:

$15.66

$17.17

Portata 52W:

$14.15

$32.59

Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile

Nome

Acadia Pharmaceuticals Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

858-558-2871

Indirizzo

12830 EL CAMINO REAL, SAN DIEGO

Dipendente

620

Cinguettio

@acadiapharma

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

ACAD's Discussions on Twitter

Confronta ACAD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ACAD	16.37	2.72B	890.53M	30.57M	80.53M	-0.92
VRTX	450.97	116.14B	10.63B	-479.80M	-1.35B	13.33
REGN	738.00	81.10B	13.85B	4.65B	3.32B	35.06
ARGX	605.92	36.23B	1.86B	-40.29M	-1.28B	-4.16
ALNY	244.89	31.59B	2.09B	-332.26M	16.06M	-4.14
BNTX	113.13	27.12B	3.30B	-501.07M	1.03B	11.54

Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-03-12	Downgrade	Mizuho	Buy → Neutral
2024-03-12	Reiterato	Needham	Buy
2024-01-30	Iniziato	Robert W. Baird	Outperform
2024-01-24	Aggiornamento	Needham	Hold → Buy
2023-12-19	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2023-12-14	Downgrade	Deutsche Bank	Buy → Hold
2023-12-13	Iniziato	Citigroup	Buy
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-11-06	Aggiornamento	Mizuho	Neutral → Buy
2023-10-17	Iniziato	UBS	Buy
2023-10-10	Aggiornamento	JP Morgan	Neutral → Overweight
2023-01-03	Aggiornamento	Guggenheim	Neutral → Buy
2022-11-04	Downgrade	Goldman	Neutral → Sell
2022-11-01	Iniziato	Loop Capital	Hold
2022-08-08	Downgrade	Citigroup	Buy → Neutral
2022-08-05	Downgrade	Citigroup	Buy → Neutral
2022-06-21	Downgrade	Jefferies	Buy → Underperform
2022-06-16	Aggiornamento	Jefferies	Hold → Buy
2022-03-16	Aggiornamento	Canaccord Genuity	Hold → Buy
2022-02-09	Aggiornamento	H.C. Wainwright	Neutral → Buy
2022-01-05	Aggiornamento	Citigroup	Neutral → Buy
2021-12-21	Downgrade	Guggenheim	Buy → Neutral
2021-11-01	Aggiornamento	Guggenheim	Neutral → Buy
2021-10-14	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Ripresa	Needham	Hold
2021-06-10	Iniziato	Berenberg	Hold
2021-04-07	Downgrade	H.C. Wainwright	Buy → Neutral
2021-04-06	Downgrade	Canaccord Genuity	Buy → Hold
2021-04-06	Downgrade	Goldman	Buy → Neutral
2021-04-06	Downgrade	Jefferies	Buy → Hold
2021-04-06	Downgrade	Mizuho	Buy → Neutral
2021-04-05	Downgrade	Raymond James	Outperform → Mkt Perform
2021-03-10	Downgrade	BofA Securities	Buy → Neutral
2021-03-09	Downgrade	Citigroup	Buy → Neutral
2021-03-09	Downgrade	Guggenheim	Buy → Neutral
2021-03-09	Reiterato	H.C. Wainwright	Buy
2021-03-09	Downgrade	Raymond James	Strong Buy → Outperform
2021-03-09	Downgrade	Stifel	Buy → Hold
2020-12-16	Iniziato	Mizuho	Buy
2020-11-16	Aggiornamento	Raymond James	Outperform → Strong Buy
2020-08-25	Iniziato	Raymond James	Outperform
2020-08-20	Iniziato	Morgan Stanley	Overweight
2020-07-07	Aggiornamento	Stifel	Hold → Buy
2020-04-16	Iniziato	Jefferies	Buy
2020-03-31	Aggiornamento	Goldman	Neutral → Buy
2020-03-06	Iniziato	Citigroup	Buy
2019-12-16	Iniziato	Guggenheim	Buy
2019-10-24	Iniziato	Oppenheimer	Perform
2019-10-01	Iniziato	RBC Capital Mkts	Outperform
2019-09-13	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2019-09-10	Aggiornamento	Canaccord Genuity	Hold → Buy
2019-07-23	Reiterato	Needham	Buy
2018-12-10	Iniziato	Canaccord Genuity	Hold
2018-09-21	Aggiornamento	Piper Jaffray	Neutral → Overweight
2018-08-09	Reiterato	Stifel	Hold
2018-08-07	Iniziato	Stifel	Hold
2018-08-06	Downgrade	Piper Jaffray	Overweight → Neutral
2017-10-06	Ripresa	Goldman	Neutral

Mostra tutto

Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie

03:16 AM

Principal Financial Group Inc. Acquires 52,340 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

03:16 AM

Nov 21, 2024

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - The Bakersfield Californian

Nov 21, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stake Decreased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat

Nov 21, 2024

When (ACAD) Moves Investors should Listen - Stock Traders Daily

Nov 21, 2024

Nov 20, 2024

Acadia Pharmaceuticals announces executive shakeup - Investing.com

Nov 20, 2024

Acadia Pharmaceuticals' Operating Chief Involuntarily Terminated Without Cause - MarketWatch

Nov 20, 2024

Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure - TipRanks

Nov 20, 2024

Acadia Pharmaceuticals announces executive shakeup By Investing.com - Investing.com UK

Nov 20, 2024

Acadia Pharma (ACAD) Chief Operating Officer to be Involuntarily Terminated Without Cause - StreetInsider.com

Nov 20, 2024

Acadia Pharma ticks lower amid Deutsche Bank downgrade after surge on patent win - MSN

Nov 20, 2024

Acadia Pharmaceuticals CFO sells shares worth $172,453 By Investing.com - Investing.com Canada

Nov 19, 2024

Acadia Pharmaceuticals' COO sells $173,630 in stock By Investing.com - Investing.com Canada

Nov 19, 2024

FY2024 Earnings Estimate for ACAD Issued By Leerink Partnrs - MarketBeat

Nov 19, 2024

Nov 16, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short Interest - MarketBeat

Nov 16, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Lowered by GSA Capital Partners LLP - MarketBeat

Nov 16, 2024

Nov 15, 2024

Acadia Pharmaceuticals Grants Stock Options, RSUs to 23 New Employees in Growth Push | ACAD Stock News - StockTitan

Nov 15, 2024

Nov 13, 2024

ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock By Investing.com - Investing.com Canada

Nov 13, 2024

ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com

Nov 13, 2024

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56 - MarketBeat

Nov 13, 2024

Nov 12, 2024

Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - Yahoo Finance

Nov 12, 2024

US Bancorp DE Has $507,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Nov 12, 2024

Nov 11, 2024

Acadia Pharmaceuticals: Proving The Naysayers Wrong (NASDAQ:ACAD) - Seeking Alpha

Nov 11, 2024

What is Leerink Partnrs' Forecast for ACAD FY2026 Earnings? - MarketBeat

Nov 11, 2024

FY2024 Earnings Estimate for ACAD Issued By HC Wainwright - MarketBeat

Nov 11, 2024

Nov 10, 2024

Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates - MSN

Nov 10, 2024

Nov 09, 2024

ACADIA Pharmaceuticals Inc. Just Recorded A 43% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

Acadia Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for ACAD - Nasdaq

Nov 08, 2024

Acadia Pharmaceuticals price target lowered to $32 from $33 at Canaccord - TipRanks

Nov 08, 2024

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Equities Analysts Issue Forecasts for ACAD FY2027 Earnings - MarketBeat

Nov 08, 2024

HC Wainwright Issues Pessimistic Estimate for ACAD Earnings - MarketBeat

Nov 08, 2024

ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Simply Wall St

Nov 08, 2024

ACADIA Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024